Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Type I Cryoglobulinemia
NCT05114109Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in cryoglobulinemic vasculitis type I, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical response at Week 20. Status: unknown.
02
Drugs
isatuximab
03
Conditions
cryoglobulinemic vasculitis type I
Beyond the preview
Go deeper on NCT05114109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114109.